Compare ACRV & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACRV | ONMD |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4M | 45.8M |
| IPO Year | 2022 | N/A |
| Metric | ACRV | ONMD |
|---|---|---|
| Price | $2.14 | $1.03 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 860.9K | 860.0K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.31 |
| 52 Week High | $3.56 | $4.22 |
| Indicator | ACRV | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 55.77 |
| Support Level | $1.49 | $0.62 |
| Resistance Level | $2.19 | $1.14 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 82.35 | 40.59 |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.